GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (STU:K6S) » Definitions » Other Gross PPE

Mira Pharmaceuticals (STU:K6S) Other Gross PPE : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Mira Pharmaceuticals Other Gross PPE?

Mira Pharmaceuticals's Other Gross PPE for the quarter that ended in Dec. 2024 was €0.00 Mil.

Mira Pharmaceuticals's annual Other Gross PPE declined from Dec. 2022 (€0.34 Mil) to Dec. 2023 (€0.01 Mil) and declined from Dec. 2023 (€0.01 Mil) to Dec. 2024 (€0.00 Mil).


Mira Pharmaceuticals Other Gross PPE Historical Data

The historical data trend for Mira Pharmaceuticals's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals Other Gross PPE Chart

Mira Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Other Gross PPE
- 0.34 0.01 -

Mira Pharmaceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - -

Mira Pharmaceuticals Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Mira Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1200 Brickell Avenue, Suite 1950 No. 1183, Miami, FL, USA, 33133
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Mira Pharmaceuticals Headlines

No Headlines